Table 1C.
HR | 95% CI | P value | |
---|---|---|---|
ST vs T | 0.04 | 0.02–0.09 | <0.01 |
Grade III vs Grade II | 1.94 | 1.19–3.14 | 0.01 |
Integr.diagn. oligo vs astro | 0.74 | 0.48–1.14 | 0.18 |
Duration clinical history >6 vs < 6 months | 0.66 | 0.42–1.03 | 0.07 |
Previous Treats. | 1.93 | 1.19–3.13 | 0.01 |
Location T. vs F. | 0.74 | 0.40–1.38 | 0.34 |
Location P. vs F. | 1.07 | 0.61–1.86 | 0.82 |
Location Ins. vs F | 1.05 | 0.62–1.79 | 0.84 |
Righ vs Left | 0.70 | 0.38–1.31 | 0.27 |
Volume mL | 1.00 | 0.99–1.00 | 0.30 |
Dominant no vs yes | 0.73 | 0.38–1.38 | 0.33 |
CC no vs yes | 0.77 | 0.49–1.22 | 0.27 |
ST, supratotal; T, Total; Integr.Diagn., integrated diagnosis; Oligo, oligodendroglioma; Astro, astrocytoma; Previous Treats., previous treatments; Location: T, temporal, F, frontal, P, parietal, Ins., insular. Dominant, dominance; CC, corpus callosum involvement.